SwePub
Sök i LIBRIS databas

  Utökad sökning

WFRF:(Palmer Richard)
 

Sökning: WFRF:(Palmer Richard) > (2015-2019) > Impact of intensifi...

LIBRIS Formathandbok  (Information om MARC21)
FältnamnIndikatorerMetadata
00004148naa a2200565 4500
001oai:DiVA.org:umu-154578
003SwePub
008181219s2019 | |||||||||||000 ||eng|
0247 a https://urn.kb.se/resolve?urn=urn:nbn:se:umu:diva-1545782 URI
0247 a https://doi.org/10.1016/j.pan.2018.10.0032 DOI
040 a (SwePub)umu
041 a engb eng
042 9 SwePub
072 7a ref2 swepub-contenttype
072 7a art2 swepub-publicationtype
1001 a Javed, Muhammad Ahsan4 aut
2451 0a Impact of intensified chemotherapy in metastatic pancreatic ductal adenocarcinoma (PDAC) in clinical routine in Europe
264 1b Elsevier,c 2019
338 a print2 rdacarrier
520 a BACKGROUND: Pancreatic ductal adenocarcinoma (PDAC) is associated with poor prognosis. Gemcitabine is the standard chemotherapy for patients with metastatic pancreatic adenocarcinoma (MPA). Randomized clinical trials evaluating intensified chemotherapies including FOLFIRINOX and nab-paclitaxel plus gemcitabine (NAB+GEM) have shown improvement in survival. Here, we have evaluated the efficacy of intensified chemotherapy versus gemcitabine monotherapy in real-life settings across Europe.METHODS: A retrospective multi-center study including 1056 MPA patients, between 2012 and 2015, from nine centers in UK, Germany, Italy, Hungary and the Swedish registry was performed. Follow-up was at least 12 months. Cox proportional Harzards regression was used for uni- and multivariable evaluation of prognostic factors.RESULTS: Of 1056 MPA patients, 1030 (98.7%) were assessable for survival analysis. Gemcitabine monotherapy was the most commonly used regimen (41.3%), compared to FOLFIRINOX (n = 204, 19.3%), NAB+GEM (n = 81, 7.7%) and other gemcitabine- or 5-FU-based regimens (n = 335, 31.7%). The median overall survival (OS) was: FOLFIRINOX 9.9 months (95%CI 8.4-12.6), NAB+GEM 7.9 months (95%CI 6.2-10.0), other combinations 8.5 months (95%CI 7.7-9.3) and gemcitabine monotherapy 4.9 months (95%CI 4.4-5.6). Compared to gemcitabine monotherapy, any combination of chemotherapeutics improved the survival with no significant difference between the intensified regimens. Multivariable analysis showed an association between treatment center, male gender, inoperability at diagnosis and performance status (ECOG 1-3) with poor prognosis.CONCLUSION: Gemcitabine monotherapy was predominantly used in 2012-2015. Intensified chemotherapy improved OS in comparison to gemcitabine monotherapy. In real-life settings, the OS rates of different treatment approaches are lower than shown in randomized phase III trials.
650 7a MEDICIN OCH HÄLSOVETENSKAPx Klinisk medicinx Kirurgi0 (SwePub)302122 hsv//swe
650 7a MEDICAL AND HEALTH SCIENCESx Clinical Medicinex Surgery0 (SwePub)302122 hsv//eng
650 7a MEDICIN OCH HÄLSOVETENSKAPx Klinisk medicinx Cancer och onkologi0 (SwePub)302032 hsv//swe
650 7a MEDICAL AND HEALTH SCIENCESx Clinical Medicinex Cancer and Oncology0 (SwePub)302032 hsv//eng
653 a Intensified chemotherapy
653 a Multicenter study
653 a Pancreatic cancer
7001 a Beyer, Georg4 aut
7001 a Le, Nha4 aut
7001 a Vinci, Alessio4 aut
7001 a Wong, Helen4 aut
7001 a Palmer, Daniel4 aut
7001 a Morgan, Robert D4 aut
7001 a Lamarca, Angela4 aut
7001 a Hubner, Richard A4 aut
7001 a Valle, Juan W4 aut
7001 a Alam, Salma4 aut
7001 a Chowdhury, Sumsur4 aut
7001 a Ma, Yuk Ting4 aut
7001 a Archibugi, Livia4 aut
7001 a Capurso, Gabriele4 aut
7001 a Maisonneuve, Patrick4 aut
7001 a Neesse, Albrecht4 aut
7001 a Sund, Malinu Umeå universitet,Kirurgi4 aut0 (Swepub:umu)masu0021
7001 a Schober, Marvin4 aut
7001 a Krug, Sebastian4 aut
7102 a Umeå universitetb Kirurgi4 org
7730 t Pancreatology (Print)d : Elsevierg 19:1, s. 97-104q 19:1<97-104x 1424-3903x 1424-3911
8564 8u https://urn.kb.se/resolve?urn=urn:nbn:se:umu:diva-154578
8564 8u https://doi.org/10.1016/j.pan.2018.10.003

Hitta via bibliotek

Till lärosätets databas

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Stäng

Kopiera och spara länken för att återkomma till aktuell vy